2023
Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes
Silver H, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, Koethe J, Niswender K, Luther J, Brown N. Effect of the glucagon‐like peptide‐1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes Obesity And Metabolism 2023, 25: 2340-2350. PMID: 37188932, PMCID: PMC10544709, DOI: 10.1111/dom.15113.Peer-Reviewed Original ResearchMeSH KeywordsAdultAppetiteBody Fat DistributionBody WeightCaloric RestrictionCardiovascular DiseasesDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsDipeptidyl-Peptidases and Tripeptidyl-PeptidasesEatingGlucagon-Like Peptide-1 ReceptorHumansHypoglycemic AgentsLiraglutideObesityPrediabetic StateSitagliptin PhosphateWeight LossConceptsGlucagon-like peptide-1 receptor agonist liraglutidePeptide-1 receptor agonist liraglutideLiraglutide groupSitagliptin groupCR groupCaloric restrictionChi-squared testDietary intakeWeight lossBody weightBody compositionDipeptidyl peptidase-4 inhibitor sitagliptinDipeptidyl peptidase-4 inhibitorsDual-energy X-ray absorptiometryEnergy X-ray absorptiometryInsulin resistance scoreBaseline body weightHomeostatic model assessmentPeptidase-4 inhibitorsCardiometabolic risk reductionBody fat distributionVisual analog scaleWeeks of interventionPersonal risk factorsX-ray absorptiometry
2002
Potential Roles of Plasminogen Activator System in Coronary Vascular Remodeling Induced by Long-term Nitric Oxide Synthase Inhibition
Kaikita K, Schoenhard JA, Painter CA, Ripley RT, Brown NJ, Fogo AB, Vaughan DE. Potential Roles of Plasminogen Activator System in Coronary Vascular Remodeling Induced by Long-term Nitric Oxide Synthase Inhibition. Journal Of Molecular And Cellular Cardiology 2002, 34: 617-627. PMID: 12054849, DOI: 10.1006/jmcc.2002.2001.Peer-Reviewed Original ResearchConceptsSystolic blood pressureNitric oxide synthase inhibitionOxide synthase inhibitionPerivascular fibrosisBlood pressurePAI-1 deficiencyCoronary perivascular fibrosisPlasminogen activator systemL-NAMENOS inhibitionSynthase inhibitionDeficient miceVascular pathologyLong-term nitric oxide synthase inhibitionNitro-L-arginine methyl esterL-NAME-induced hypertensionLong-term NOS inhibitionPlasma TGF-beta1 levelsPlasminogen activator inhibitor-1-deficient miceStructural vascular changesTGF-beta1 levelsLong-term treatmentTissue-type plasminogen activator-deficient miceWeek study periodActivator systemG protein-coupled receptor kinase 4 gene variants in human essential hypertension
Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, Williams SM, Gainer J, Brown NJ, Hazen-Martin D, Wong LJ, Robillard JE, Carey RM, Eisner GM, Jose PA. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proceedings Of The National Academy Of Sciences Of The United States Of America 2002, 99: 3872-3877. PMID: 11904438, PMCID: PMC122616, DOI: 10.1073/pnas.062694599.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood PressureBody WeightCells, CulturedCHO CellsCricetinaeCyclic AMPFemaleG-Protein-Coupled Receptor Kinase 4Heart RateHeterotrimeric GTP-Binding ProteinsHumansHypertensionImmunohistochemistryKidney Function TestsKidney Tubules, ProximalMaleMiceMice, TransgenicOrgan SizePolymorphism, Single NucleotideProtein Serine-Threonine KinasesReceptors, Dopamine D1Signal TransductionConceptsHuman essential hypertensionEssential hypertensionGenetic hypertensionProximal tubulesG-protein-coupled receptor kinase activityEnzyme complexUrinary sodium excretionRenal dopaminergic systemG protein-coupled receptor kinasesProtein-coupled receptor kinasesWild-type geneAbility of dopamineRenal proximal tubulesReceptor kinase activitySodium excretionDopaminergic actionsHypotensive effectChinese hamster ovary cellsDopamine receptorsDopaminergic systemHypertensionLike agonistsElectrolyte balanceTransgenic miceHamster ovary cells
2001
Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase Inhibition
Kaikita K, Fogo A, Ma L, Schoenhard J, Brown N, Vaughan D. Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase Inhibition. Circulation 2001, 104: 839-844. PMID: 11502712, DOI: 10.1161/hc3301.092803.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlood PressureBody WeightCollagenCoronary VesselsEnzyme InhibitorsFibrosisHemodynamicsHypertensionHypertrophy, Left VentricularMaleMiceMice, Inbred C57BLMice, KnockoutNG-Nitroarginine Methyl EsterNitric Oxide SynthasePlasminogen Activator Inhibitor 1Reverse Transcriptase Polymerase Chain ReactionRNA, MessengerTimeConceptsPlasminogen activator inhibitor-1Systolic blood pressureLong-term NOS inhibitionBlood pressurePAI-1 deficiencyNitric oxide synthaseCoronary perivascular fibrosisPerivascular fibrosisNOS inhibitionWT miceLong-term nitric oxide synthase inhibitionNitro-L-arginine methyl esterNitric oxide synthase inhibitionWild-type male miceControl WT miceStructural vascular changesOxide synthase inhibitionArteriosclerotic cardiovascular diseaseDevelopment of fibrosisPAI-1 activityNew therapeutic strategiesActivator inhibitor-1Cardiac type ILong-term inhibitionPrevents hypertension